The Food and Drug Administration has announced some major changes to the review process for drug developers in the United States. It could cut down the time from 10 to 12 months for a review to just ...
On September 3, 2025, the US Food and Drug Administration (FDA) announced a new process to support the development of drugs intended to treat rare genetic diseases. The Rare Disease Evidence ...
The FDA is implementing a new pilot program that could incentivize development of certain new drugs by dramatically shortening their regulatory reviews. But to qualify, a drug must address specified ...
The FDA named the first nine products to undergo a new expedited review process that takes 1 to 2 months, the agency announced on Thursday. The nine companies selected to participate in the FDA ...
The U.S. Food and Drug Administration (FDA) announced its Commissioner's National Priority Voucher (CNPV) program. What Happened: The FDA aims to modernize its regulatory framework to meet emerging ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results